Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 2/20 | 0.58 |
| ▸ | GHSR | Q92847 | 4/20 | 0.56 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.55 |
| ▸ | IL23R | Q5VWK5 | 10/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30518071 | 0.94 | NPBWR1 (0.64) | NPBWR1IL23R | |
| SCHEMBL29419491 | 0.93 | NPBWR1 (0.58) | NPBWR1GHSRPRMT1IL23R | |
| SCHEMBL29832285 | 0.93 | NPBWR1 (0.58) | NPBWR1GHSRPRMT1IL23R | |
| SCHEMBL30518165 | 0.93 | NPBWR1 (0.64) | NPBWR1IL23R | |
| SCHEMBL30518095 | 0.93 | NPBWR1 (0.64) | NPBWR1IL23R | |
| SCHEMBL30866237 | 0.92 | NPBWR1 (0.55) | NPBWR1GHSRPRMT1IL23R | |
| SCHEMBL29419958 | 0.92 | GHSR (0.61) | GHSR | |
| SCHEMBL29480592 | 0.91 | OPRD1 (0.57) | NPBWR1PRMT1IL23R | |
| SCHEMBL29699792 | 0.91 | GHSR (0.56) | GHSRPRMT1 | |
| SCHEMBL29702283 | 0.91 | GHSR (0.56) | GHSRPRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310521-A1 | COMBINATION COMPRISING BACILLUS AND AN ESSENTIAL OIL AND METHODS FOR MAKING AND USING | PHIBRO ANIMAL HEALTH CORPORATION (US) | 2023-10-05 | — | — | US | disclosed |
| WO-2023192262-A1 | A COMBINATION COMPRISING BACILLUS AND AN ESSENTIAL OIL AND METHODS FOR MAKING AND USING | PHIBRO ANIMAL HEALTH CORPORATION (US) | 2023-10-05 | — | — | WO | disclosed |
| US-11723919-B2 | Composition or combination comprising anionic dietary supplement and 25-hydroxy vitamin D | PHIBRO ANIMAL HEALTH CORPORATION (US) | 2023-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11723919-B2 | Composition or combination comprising anionic dietary supplement and 25-hydroxy vitamin D | VDR, CYP24A1, GC | NPBWR1 4444/4885GHSR 750/4885PRMT1 920/4885 |
| US-20230310521-A1 | COMBINATION COMPRISING BACILLUS AND AN ESSENTIAL OIL AND METHODS FOR MAKING AND USING | CHIA, YBX3, XPA | NPBWR1 2439/4885GHSR 985/4885PRMT1 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.